Glasner, Ariella
Rose, Samuel A.
Sharma, Roshan
Gudjonson, Herman
Chu, Tinyi http://orcid.org/0000-0003-3369-6692
Green, Jesse A.
Rampersaud, Sham http://orcid.org/0000-0001-7473-4144
Valdez, Izabella K.
Andretta, Emma S.
Dhillon, Bahawar S.
Schizas, Michail
Dikiy, Stanislav http://orcid.org/0000-0002-8287-6561
Mendoza, Alejandra
Hu, Wei http://orcid.org/0000-0002-0392-6939
Wang, Zhong-Min http://orcid.org/0000-0002-5538-1969
Chaudhary, Ojasvi http://orcid.org/0000-0003-1434-2506
Xu, Tianhao
Mazutis, Linas
Rizzuto, Gabrielle http://orcid.org/0000-0003-3052-0253
Quintanal-Villalonga, Alvaro http://orcid.org/0000-0002-7234-3446
Manoj, Parvathy
de Stanchina, Elisa
Rudin, Charles M. http://orcid.org/0000-0001-5204-3465
Pe’er, Dana http://orcid.org/0000-0002-9259-8817
Rudensky, Alexander Y. http://orcid.org/0000-0003-1280-2898
Article History
Received: 25 March 2022
Accepted: 5 April 2023
First Online: 1 May 2023
Change Date: 13 September 2023
Change Type: Update
Change Details: In the version of this article initially published, Supplementary Table 17 was missing HTAN sample identifiers, which are now amended in the table accompanying this article online.
Competing interests
: A.Y.R. is a member of SAB, and has equity in Surface Oncology, RAPT Therapeutics, Sonoma Biotherapeutics, Santa Ana Bio and Vedanta Biosciences and is an SAB member of BioInvent and Amgen; A.Y.R. holds a therapeutic T<sub>reg</sub> cell depletion IP licensed to Takeda. C.M.R. has consulted regarding oncology drug development with AbbVie, Amgen, Astra Zeneca, D2G, Daiichi Sankyo, Epizyme, Genentech/Roche, Ipsen, Jazz, Kowa, and Merck, and is a member of the SAB of Auron, Bridge Medicines, Earli, and Harpoon Therapeutics. D.P is a member of the SAB and has equity in Insitro. The remaining authors declare no competing interests.